Skip to content

AYURVEDIC MANAGEMENT OF GLAUCOMA

ROLE OF CHAKSHUSYA-RASAYANA (NEUROPROTECTIVE) EFFECT IN THE MANAGEMENT OF PROGRESSIVE GLAUCOMATOUS OPTIC NEUROPATHY-A CLINICAL STUDY

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2013/06/003725
Enrollment
100
Registered
2013-06-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Neuro protective role of ayurvedic management in PRIMARY OPEN ANGLE GLAUCOMA

Interventions

Intervention1: -Jeevantyadi Taila Nasya Karma (A H Utt 13/51-53) - Goghritha Tarpana - VARA FORTE Powder: -First Deepana-Pachana with Chitrakadi Vati (for 3-5) days. -Sadyo virechana with Dashamoola K

Sponsors

IPGT RA GAU JAMNAGAR
Lead Sponsor
Prof K S Dhiman
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients aged between 40-70 years. 2. Patients of POAG having IOP 21mm hg with GON. 3. GON of mild to early severe stage (Grade 1-Grade 3). 4. Patients with IOP >30, having parapapillary changes, RNFL defects and having a vertical CDR 0.4 or more who are glaucoma suspects (Ocular Hypertension With High Risk of POAG) are also included in the study.

Exclusion criteria

Exclusion criteria: 1. All types of ACG are excluded. 2. End stage GON (Grade 4) excluded from the study. 3. Ocular Hypertension having low/moderate risk of POAG. 4. Secondary and development glaucoma including exfoliative glaucoma, pigmentary glaucoma, trauma induced, inflammatory glaucoma are exclude from the study. 5. POAG with advanced stage of optic atrophy and profound visual loss/blindness are excluded. 6. POAG associated with any other chorioretinal lesions like myopic degeneration, atypical RP, BRVO, Chorio-Retinitis etc., are excluded from the study. 7.OAG associated with optic disc lesions like-Drusen, Coloboma, Papillitis, Papilloedema and any compressive optic nerve lesions are excluded.

Design outcomes

Primary

MeasureTime frame
1.Blurred Vision 2. Frequent changes in presbyopic glasses 3. Visual Acuity 4. Applanation Tonometry 5. Direct & Indirect Ophthalmoscopic Examination 6. Goldmannâ??s Automated Perimetry 7. Optical Coherence Topography Timepoint: ALL PARAMETERS ARE ASSESSED AS BASELINE BEFORE STARTING TREATMENT AND AFTER COMPLETION OF 3 MONTHS OF TREATMENT.

Secondary

MeasureTime frame
1.Blurred Vision 2. Frequent changes in presbyopic glasses 3. Visual Acuity 4. Applanation Tonometry 5. Direct & Indirect Ophthalmoscopic Examination 6. Goldmannâ??s Automated Perimetry 7. Optical Coherence Topography Timepoint: ALL PARAMETERS ARE ASSESSED BEFORE (BASELINE) TREATMENT AND AFTER 3 MONTHS OF TREATMENT.

Countries

India

Contacts

Public ContactProf K S Dhiman

IPGT & RA, GAU, Jamanagar

dr_ks_dhiman@yahoo.co.in

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026